Valuation: Acura Pharmaceuticals, Inc.

Market Cap 3.28M 2.87M 2.65M 2.45M 4.64M 313M 4.72M 31.64M 12.41M 154M 12.31M 12.04M 530M P/E 2020
-5.25x
P/E 2021 -25x
Enterprise Value 3.41M 2.99M 2.76M 2.55M 4.83M 326M 4.91M 32.94M 12.92M 160M 12.82M 12.54M 552M EV / Sales 2020
2.91x
EV / Sales 2021 20.9x
Free-Float
98.31%
Yield 2020 *
-
Yield 2021 -
Manager TitleAgeSince
Chief Executive Officer 67 2011-03-31
Director of Finance/CFO 62 2024-07-31
Chief Tech/Sci/R&D Officer 69 2009-01-31
Director TitleAgeSince
Chairman 75 1996-09-30
Director/Board Member 55 2002-11-30
Director/Board Member 83 1998-02-28
Change 5-day change 1-year change 3-year change Capi.($)
-.--%+4.44% - - 6.66K
-4.14%-8.06%+57.35%+117.24% 56.98B
+1.84%-0.66%+75.79%+93.87% 53.58B
-2.24%+3.59%+19.60%+466.72% 25.63B
-1.60%-6.21%-19.69%-14.84% 23.51B
+2.43%+1.06%+47.70%-0.11% 19.43B
-3.19%0.00%+33.99%-26.87% 18.12B
-6.84%+2.18%+195.12%+357.18% 16.46B
+8.74%+3.51%+53.81% - 14.13B
-1.05%+1.16%+25.08%+196.28% 14.35B
Average -0.60%+1.16%+54.31%+148.68% 26.91B
Weighted average by Cap. -1.02%+0.29%+54.68%+138.25%

Financials

2020 2021
Net sales 3.57M 3.13M 2.88M 2.66M 5.05M 340M 5.14M 34.45M 13.51M 168M 13.4M 13.11M 577M 1.56M 1.37M 1.26M 1.17M 2.21M 149M 2.25M 15.08M 5.92M 73.43M 5.87M 5.74M 253M
Net income -1.21M -1.06M -976K -902K -1.71M -115M -1.74M -11.66M -4.57M -56.75M -4.54M -4.44M -195M -879K -770K -710K -656K -1.24M -83.83M -1.26M -8.48M -3.33M -41.29M -3.3M -3.23M -142M
Net Debt 5.86M 5.13M 4.73M 4.37M 8.29M 558M 8.43M 56.51M 22.17M 275M 21.99M 21.51M 947M 135K 118K 109K 101K 191K 12.87M 194K 1.3M 511K 6.34M 507K 496K 21.83M
Logo Acura Pharmaceuticals, Inc.
Acura Pharmaceuticals, Inc. is a drug delivery company engaged in the research, development, and commercialization of technologies and products to address the safe use of medications. Its platform technologies include LIMITX Technology, AVERSION Technology, and IMPEDE Technology. Its LIMITX Technology is designed to minimize the risks and side effects associated with overdose by retarding the release of active drug ingredients when too many tablets are accidentally or purposefully ingested. The LIMITX Technology is in development with hydrocodone bitartrate and acetaminophen (also known as LTX-03) as the lead product candidates. Its AVERSION Technology is to address methods of product tampering associated with opioid abuse by incorporating gelling ingredients and irritants into tablets to discourage abuse by snorting and provide barriers to abuse by injection. Its IMPEDE Technology is directed at minimizing the extraction and conversion of pseudoephedrine tablets into methamphetamine.
Employees
-